CZC24832 is primarily used in research settings as a selective inhibitor of the KAT6A and KAT6B histone acetyltransferases. It plays a significant role in epigenetic studies, particularly in understanding chromatin regulation and gene expression. By inhibiting KAT6 enzymes, CZC24832 induces cell cycle arrest and promotes cellular senescence in certain cancer cell lines, making it a valuable tool in oncology research. It has shown potential in studies related to leukemia and solid tumors, where dysregulation of KAT6 genes contributes to disease progression. Its application is mainly focused on preclinical investigations to explore new therapeutic strategies targeting epigenetic modifiers.